1. Home
  2. PAI vs GNLX Comparison

PAI vs GNLX Comparison

Compare PAI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Investment Grade Income Fund Inc.

PAI

Western Asset Investment Grade Income Fund Inc.

N/A

Current Price

$11.83

Market Cap

114.7M

Sector

Finance

ML Signal

N/A

Logo Genelux Corporation

GNLX

Genelux Corporation

N/A

Current Price

$2.51

Market Cap

123.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAI
GNLX
Founded
1973
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.7M
123.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PAI
GNLX
Price
$11.83
$2.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
18.0K
330.7K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
4.78%
N/A
EPS Growth
N/A
9.47
EPS
N/A
N/A
Revenue
N/A
$8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.72
$2.29
52 Week High
$13.01
$8.54

Technical Indicators

Market Signals
Indicator
PAI
GNLX
Relative Strength Index (RSI) 39.13 39.01
Support Level $11.72 $2.33
Resistance Level $12.35 $2.97
Average True Range (ATR) 0.08 0.16
MACD -0.01 -0.01
Stochastic Oscillator 11.54 4.40

Price Performance

Historical Comparison
PAI
GNLX

About PAI Western Asset Investment Grade Income Fund Inc.

Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. Its primary investment objective is to seek a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. To a lesser extent, the fund also invests in privately placed debt securities and in certain equity securities. Capital appreciation is its secondary investment objective. The fund invests a majority of its net assets in fixed income securities that are rated in the Baa or BBB categories or above at the time of purchase by one or more Nationally Recognized Statistical Rating Organizations (NRSROs) or unrated securities of comparable quality at the time of purchase (as determined by the investment adviser).

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: